New Once-a-Day pill could ease lifelong burden of rare copper disease

NCT ID NCT07465718

Not yet recruiting Disease control Sponsor: Orphalan Source: ClinicalTrials.gov ↗

Summary

This study is testing a new, once-daily version of a copper-removing drug (trientine) against the current standard treatment (d-Penicillamine) for people newly diagnosed with Wilson's disease. It aims to see if the new formulation is effective, safe, and easier to stick with than treatments taken multiple times a day. The trial will enroll about 38 children (8+) and adults who have not yet started standard copper-removing therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WILSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.